Thin Film Drug Manufacturing Market - Forecast(2024 - 2030)
Thin Film Drug Manufacturing Market Overview
The Thin Film Drug Manufacturing Market size is estimated to reach $17.7 billion by 2028, growing at a CAGR of 8.1% during the forecast period 2023-2028. Thin film has risen as a progressive drug delivery technique that makes medication easy to swallow. MonoSol Rx has been granted a strategic U.S. patent for a thin film manufacturing process in the U.S. Thin film manufacturing companies in the U.S., include Nova Thin Film Pharmaceuticals and Pfizer Inc. The thin film drug manufacturing market in the U.S. is fuelled by technological progress in pharmaceutical research with emerging demand for novel drug delivery. The thin film drug manufacturing market in North America occupies the dominant market share in the Global Thin Film Drug Manufacturing Market. The prominence of the thin film drug manufacturing market in the U.S. is set to drive its growth. The rising demand for profit-generating drug delivery systems would propel the growth of the Thin Film Drug Manufacturing Industry during the forecast period 2023-2028.
Thin Film Drug Manufacturing Market Report Coverage
The report: “Thin Film Drug Manufacturing
Market Report - Forecast (2023-2028)” by IndustryARC, covers an
in-depth analysis of the following segments in the Thin Film Drug Manufacturing Market.
Key Takeaways
- Geographically, North America (Thin Film Drug Manufacturing market share) accounted for the highest revenue share in 2021 and it is poised to dominate the market over the period of 2023-2028, owing to the emerging application of the thin film manufacturing process in the U.S.
- Thin Film Drug Manufacturing Market growth is being driven by a growing number of investments in R&D programs by thin film manufacturing companies in the U.S. However, reduced drug loading capacity for a lesser powerful medication provided at high doses restricts the application of thin films at times. It is one of the major factors hampering the growth of the Thin Film Drug Manufacturing Market.
- Thin Film Drug Manufacturing Market Detailed Analysis of the Strengths, Weaknesses and Opportunities of the prominent players operating in the market would be provided in the Thin Film Drug Manufacturing Market report.
Thin Film Drug Manufacturing Market: Market Share (%) by Region, 2021
For more details on this report - Request for Sample
Thin Film Drug Manufacturing Market Segment Analysis - By Product Type
The Thin Film Drug Manufacturing Market
based on product type can be further segmented into Oral
Thin Film and Transdermal Thin Film. The Oral Thin Film Segment held the largest share of the Thin Film Drug Manufacturing market in 2021. This growth is owing to the surging application of oral thin film
drugs where oral thin film medications are being put on the oral mucosal
tissue or tongue of patients. The soaring demand for oral thin film drugs due to technological progress in these products is further propelling the growth of
the Oral Thin Film segment.
Furthermore, the Transdermal Thin Film
segment is estimated to grow with the fastest CAGR of 10.1% during the forecast
period 2023-2028. It is due to the soaring advantages of transdermal drug delivery, involving
developments in transdermal delivery technology and altering the requirements of
patients.
Thin Film Drug Manufacturing Market Segment Analysis - By Indication
The Thin Film Drug
Manufacturing Market based on indication can be further segmented into Schizophrenia, Migraine and Opioid Dependence. The Schizophrenia Segment held the largest share of the Thin Film Drug
Manufacturing market in 2021. This growth is driven by the increasing
predominance of schizophrenia. The surging application of thin-film drug
delivery is further propelling the growth of this
segment.
Furthermore, the Migraine
segment is estimated to grow with the fastest CAGR of 9.3% during the forecast period 2023-2028. This is due to the formulation of Propranolol hydrochloride oral thin films for migraine
prophylaxis with the intention of developing the dosage form to decrease the dose
by bypassing its earliest pass metabolism.
Thin Film Drug Manufacturing Market Segment Analysis - By Geography
The Thin Film Drug Manufacturing Market, based on geography, can be further segmented into North America, Europe, Asia-Pacific, South America and the Rest of the World. North America (Thin Film Drug Manufacturing Market) dominated the Thin Film Drug Manufacturing market with a 35% share of the overall market in 2021. The growth of this region is driven by the extensive application of thin film manufacturing processes in the US of the North American region. The existence of thin film manufacturing companies in the US, like Nova Thin Film Pharmaceuticals, is further propelling the growth of the thin film drug manufacturing market in the US, thereby contributing to the Thin Film Drug Manufacturing Market in North America.
Furthermore, the Asia-Pacific region is estimated to be the region with the fastest CAGR over the forecast period 2023-2028. This growth is fueled by factors like the principal contribution of countries like India in the Asia-Pacific region. The novel product launches are further fueling the progress of the Thin Film Drug Manufacturing Market in the Asia-Pacific region.
Thin Film Drug Manufacturing Market Drivers
Surging Applications of Thin Films:
Considering oral drug strip development, typically 5% w/w to 30% w/w of active pharmaceutical ingredients can be included in the oral strip. Thin films have been recognized as an alternative to traditional dosage forms. The thin films are thought to be convenient to swallow, self-administrable and fast-dissolving dosage form, all of which make it a versatile platform for drug delivery. This delivery system has been utilized for both systemic and local action through numerous routes like oral, buccal, sublingual, ocular and transdermal routes. The surging applications of Thin Film Drug Manufacturing are therefore fueling the growth of the Thin Film Drug Manufacturing Market during the forecast period 2023-2028.
Soaring Utilization of Oral Films:
Fast-dissolving oral films are ultra-thin (50-150um), around the size of a postage stamp and dissolve in the oral cavity within one minute subsequent to contacting saliva. This assures accelerated absorption and instantaneous bioavailability of the medicine. Buccal films are intended for remaining in contact with the cheek mucosa for a longer period of time. The soaring utilization of oral films is therefore driving the growth of the Thin Film Drug Manufacturing Industry. It would further contribute to the Thin Film Drug Manufacturing Industry Outlook during the forecast period 2023-2028.
Thin Film Drug Manufacturing Market Challenge
High Cost of Thin Films:
Saliva stimulants are utilized alone or integrated to accomplish the desired impact and these typically constitute around 2-6% w/w of the complete oral film. The soaring cost of treatment is a key limitation. The high cost of thin film drugs in comparison with traditional drug dosages is likely to discourage end-users. This may result in therapeutic failure, non-reproducible impacts and toxicity to the patient at times. These issues are hampering the growth of the Thin Film Drug Manufacturing Market.
Thin Film Drug Manufacturing Industry Outlook
R&D activities of progressive products, the extension of production facilities and rising geographical reach are key strategies adopted by players in the Thin Film Drug Manufacturing Market. The top 10 companies in the Thin Film Drug Manufacturing market are:
- Pfizer, Inc.
- Novartis AG
- Wolters Kluwer
- Solvay
- Allergan plc
- Sumitomo Dainippon Pharma Co. Ltd.
- IntelGenx Corp.
- ZIM Laboratories Limited
- Aquestive Therapeutics
- Indivior PLC
Recent Developments
- In May 2022, Pfizer Inc. and Biohaven Pharmaceutical Holding Company Ltd. declared that the firms have entered into a definitive agreement. Under this agreement, Pfizer would acquire Biohaven. Biohaven is the manufacturer of NURTEC® ODT.
- In March 2022, Pfizer Inc. acquired Arena Pharmaceuticals. Arena Pharmaceuticals is a clinical phase firm. It establishes creative promising therapies for the treatment of numerous immuno-inflammatory ailments.
- In April 2021, Pfizer Inc. declared the acquisition of Amplyx Pharmaceuticals, Inc. The lead compound of Amplyx is Fosmanogepix (APX001). It is a new investigational asset under development for the treatment of invasive fungal infections.
Relevant Reports:
Thin
Film Piezoelectric Devices Market - Industry Analysis, Market Size, Share,
Trends, Application Analysis, Growth and Forecast Analysis
Report
Code: AIR 0350
Thin
Film And Printed Battery Market - Industry Analysis, Market Size, Share,
Trends, Application Analysis, Growth and Forecast Analysis
Report Code: ESR 39681
Thin
Film Transistor Market - Industry Analysis, Market Size, Share, Trends,
Application Analysis, Growth and Forecast Analysis
Report Code:
ESR 29850
For more Lifesciences and Healthcare Market reports, please click here